Merck, Modifi

Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Modifi Biosciences Acquired by Merck
Modifi Biosciences, Inc. ("Modifi Biosciences"), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences
Modifi on Wednesday said the deal gives Rahway, N.J., drugmaker Merck access to preclinical compounds designed to exploit DNA repair defects in hard-to-treat cancers, including glioblastoma, the most aggressive type of brain tumor.
Merck buys Modifi for $30M plus up to $1.3B in potential payments
Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and up to $1.3B in potential milestone payments. Modifi, a spinout of Yale University,
Merck Keytruda cleared in EU for two new indications in gynecologic cancers
Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat ...
Outsourcing-pharma8h
Merck acquires cancer startup in a deal worth up to $1.3 billion
Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...
FierceBiotech43m
Arcus' new HIF-2a data in kidney cancer hint at potential edge over Merck's Welireg, analysts say
With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...
Pfizer, Merck Pneumonia Shots Get Backing for Adults Over 50
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...
bovnews5h
Merck & Co Inc (MRK) Stock Settles at $106.38: What’s Contributing to This Price Point?
Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...
FiercePharma21h
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
Merck: EC approves two new indications for Keytruda
Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in ...
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines.
Business Wire7h
Merck Foundation Awarded the “NGO of the Year 2024” for Leading Community Empowerment in Africa by Voters’ Choice
Merck Foundation Awarded the “NGO of the Year 2024” for Leading Community Empowerment in Africa by Voters’ Choice ...
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi has agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to ...